Is Bimzelx Approved for Psoriatic Arthritis?
Bimzelx (bimekizumab-bkzx) is FDA-approved for active psoriatic arthritis (PsA) in adults. The approval came in 2023, based on Phase 3 BE OPTIMAL and BE COMPLETE trials showing significant improvements in joint and skin symptoms compared to placebo.[1][2]
How Does Bimzelx Work in PsA?
Bimzelx targets both IL-17A and IL-17F cytokines, which drive inflammation in PsA. This dual blockade reduces joint pain, swelling, enthesitis, dactylitis, and psoriasis plaques. In trials, 45-50% of patients achieved ACR50 response (50% improvement in American College of Rheumatology criteria) at week 16.[1][3]
Who Can Use Bimzelx for PsA?
It's indicated for adults with active PsA, including those who have responded inadequately to TNF inhibitors. No specific prior treatment is required. Dosing starts with 160 mg subcutaneous injections every 4 weeks, then every 8 weeks.[1]
What Do Trial Results Show?
- BE OPTIMAL: 43.1% ACR50 vs. 20.7% placebo; minimal radiographic progression.[2]
- BE COMPLETE: 38.8% ACR50 in TNF-experienced patients vs. 16% placebo.[2]
Common side effects include upper respiratory infections (15-20%), oral candidiasis (7-10%), and herpes infections (5%). Serious risks involve infections and hypersensitivity.[1]
How Does Bimzelx Compare to Other PsA Treatments?
| Treatment | Mechanism | ACR50 at Week 16 (approx.) | Key Notes |
|-----------|-----------|-----------------------------|-----------|
| Bimzelx | IL-17A/F | 45% | Dual IL-17 blockade; strong skin clearance |
| Cosentyx (secukinumab) | IL-17A | 40-45% | Single IL-17A; longer market history |
| Taltz (ixekizumab) | IL-17A | 40% | Similar skin efficacy |
| Tremfya (guselkumab) | IL-23 | 35-40% | Targets upstream cytokine |
Bimzelx shows comparable or better joint/skin responses, especially in TNF-failures.[3][4]
When Can Patients Access Bimzelx?
Available since 2023 in the US via UCB Pharma. List price is about $6,000-7,000 per month before discounts; patient assistance programs exist.[5] No pediatric approval for PsA.
What About Patents and Biosimilars?
Bimzelx's key composition-of-matter patent (US 8,119,127) expires in 2032, with formulation patents into 2038. No biosimilars approved yet; challenges could accelerate entry.[6]
Sources
[1]: Bimzelx Prescribing Information (FDA)
[2]: New England Journal of Medicine - BE OPTIMAL/BE COMPLETE
[3]: Ritchlin et al., Lancet (2023)
[4]: Head-to-head PsA meta-analysis, Rheumatology (2024)
[5]: UCB Pricing Info
[6]: DrugPatentWatch - Bimzelx Patents